Author's response to reviews

Title: Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: A phase I trial

Authors:

Tetsuji Terazawa (terasawat@poh.osaka-med.ac.jp)
Shunsuke Kondo (shkondo@ncc.go.jp)
Hiroko Hosoi (hhosoi@ncc.go.jp)
Chigusa Morizane (cmorizan@ncc.go.jp)
Satoshi Shimizu (sashimiz@east.ncc.go.jp)
Shuichi Mitsunaga (smitsuna@east.ncc.go.jp)
Masafumi Ikeda (masikeda@east.ncc.go.jp)
Hideki Ueno (hiueno@ncc.go.jp)
Takuji Okusaka (tokusaka@ncc.go.jp)

Version: 2 Date: 23 October 2013

Author's response to reviews: see over
Dear Editors:

I, along with my coauthors, would like to ask you to consider the attached manuscript entitled “Transarterial infusion chemotherapy with cisplatin plus S-1 for treating hepatocellular carcinoma: Results of a phase I trial” for publication in BMC cancer as a Research articles.

Limited effective treatment options exist for advanced hepatocellular carcinoma (HCC). S-1, cisplatin, and transcatheter arterial infusion have all been shown to be effective in isolation against hepatocellular tumors. However, combination therapy with S-1, cisplatin, and transcatheter arterial infusion is expected to be further efficient. We therefore conducted a clinical phase I trial of transcatheter arterial infusion with cisplatin plus S-1 for patients with advanced HCC who are intolerant or refractory to sorafenib. We determined the recommended dose for subsequent phase II studies on the basis of the maximum-tolerated dose and dose-limiting toxicity.

We believe that the findings of this study are relevant to the scope of your journal and will be of interest to its readership.

If it is not too much of a problem, please consider, as potential referees, prof. Junji Furuse (Kyorin University. jfuruse@ks.kyorin-u.ac.jp).

This manuscript has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal. All study participants provided informed consent, and the study design was approved by the appropriate ethics review boards. All the authors have approved the manuscript and agree with submission to your esteemed journal. There are no conflicts of interest to declare.

We described below with a point-by-point description of the changes made.
1. We added authors’ contributions section after the Competing Interests section.
2. We added figure legends after references.

I look forward to hearing from you at your earliest convenience.

Sincerely,

Shunsuke Kondo
Hepatobiliary and Pancreatic Oncology Division
National Cancer Center Hospital
5-1-1 Tsukiji Chuo-ku
Tokyo 104-0045, Japan
Phone: +81-3-3542-2511
Fax: +81-3-3542-3815
E-mail: shkondo@ncc.go.jp